Based on these data and evidence from randomized-controlled trials, three GLP-1 RAs were approved for treatment of DM 2 patients with concomitant CVD or very high/high CV risk and found a place in European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines from 2019—liraglutide, semaglutide, and dulaglutide [117]. The gene discussed is GLP1R; the disease is diabetes mellitus.